Gujarat Kidney And Super Speciality Limited (GKSL)

Healthcare · Healthcare Services · NSE · Updated 15 July 2026

₹132.74

🎯 Key Takeaways

GKSL is transitioning from a domestically focused kidney specialty provider to a diversified healthcare services player with international expansion into the UAE, marked by strong financial momentum and strategic inorganic growth. The company has demonstrated robust revenue and profitability growth, supported by audited results and active capital deployment toward hospital acquisitions.
⚠️ Integration risk associated with the Blue Tree Clinics acquisition in the UAE, including cultural alignment, regulatory compliance, and realization of

Market Cap

₹1,082

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About GKSL 📊 Interactive Charts

📖 The Story

GKSL is transitioning from a domestically focused kidney specialty provider to a diversified healthcare services player with international expansion into the UAE, marked by strong financial momentum and strategic inorganic growth. The company has demonstrated robust revenue and profitability growth, supported by audited results and active capital deployment toward hospital acquisitions.

📰 What's Happening

In the last quarter, GKSL's board approved a 51% stake acquisition in UAE-based Blue Tree Clinics LLC for Rs 19.83 crore, targeting a polyclinic specializing in plastic surgery, laser cosmetic, dental, and chiropractic services, with the target reporting Rs 3.14 crore net profit in FY2025. The acquisition is to be completed within 50 days and requires shareholder approval via postal ballot for IPO object variation. Concurrently, Dr. Paresh Dhoti was appointed as an additional non-executive independent director, subject to AGM approval. Earlier, the company confirmed no material deviation in fund utilization from its ₹250.80 crore equity issue, with proceeds allocated to hospital acquisitions and inorganic growth. The trading window was closed ahead of Q1 results disclosure in compliance with SEBI insider norms.

Source: Stock Announcements

🔮 Management Outlook & What's Next

Management expressed confidence in sustained growth through geographic diversification and service line expansion, particularly via the Blue Tree Clinics acquisition in the UAE. They indicated that the integration of the target and realization of synergies are central to their strategic vision, with completion expected within 50 days pending shareholder approval. The appointment of Dr. Paresh Dhoti was highlighted as a move to strengthen governance and bring specialized expertise. No formal long-term financial targets were provided, but management emphasized continued capital efficiency and expansion in high-margin specialties.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Apollo Hospitals Enterprise Limited	1.16 L Cr	64.5	20.5%	21.9%	0.64
Max Healthcare Institute Limited	1.02 L Cr	101.2	—	—	—
Fortis Healthcare Limited	72,752	94.6	—	—	—
Aster DM Healthcare Limited	39,048	7.1	—	—	—
Narayana Hrudayalaya Ltd.	37,625	47.7	—	—	—
Global Health Limited	33,405	65.8	—	—	—
Krishna Institute of Medical Sciences Limited	30,477	80.3	—	—	—
Dr. Lal Path Labs Ltd.	26,871	63.6	—	—	—
Syngene International Limited	18,295	36.3	—	—	—
Dr. Agarwal's Health Care Limited	14,266	88.8	14.9%	6.8%	0.13

🔗 Peer Stock Analyses

APOLLOHOSP MAXHEALTH FORTIS ASTERDM NH

⚠️ Risk Factors

1. Integration risk associated with the Blue Tree Clinics acquisition in the UAE, including cultural alignment, regulatory compliance, and realization of synergies. 2. Execution risk around the 50-day closing timeline and shareholder approval for the IPO object variation, which could delay or derail the transaction. 3. Exposure to international markets introduces foreign exchange and geopolitical risks not present in the domestic operations. 4. Dependence on continued revenue growth from acquired entities to justify valuation and expansion strategy, with no guarantee of sustained profitability post-acquisition.

📋 Recent Filings

🧠 Analyst's Read

GKSL is executing a clear strategy to scale through inorganic growth and geographic expansion, supported by strong audited financial performance and improving margins. The next critical milestone is the successful closing of the Blue Tree Clinics acquisition and shareholder approval for the IPO object variation. Investors should monitor execution progress, integration timelines, and updates on the AGM agenda. While fundamentals appear healthy, the pace and success of international expansion will be key determinants of future performance.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on GKSL

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when GKSL files new disclosures

Track GKSL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track GKSL — Free

Free account · 2 AI queries/day